This trial is testing a new tool to see if it can help patients with Alzheimer's by disrupting the blood-brain barrier.
1 Primary · 0 Secondary · Reporting Duration: 5 years
Experimental Treatment
30 Total Participants · 1 Treatment Group
Primary Treatment: Blood Brain Barrier (BBB) Disruption · No Placebo Group · N/A
Age 50 - 85 · All Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: